Avanti Biosciences, Inc. is a preclinical-stage biopharmaceutical company - and a current resident of JLabs San Diego - structured around development of new classes of drugs for treating CNS diseases including Alzheimers Disease and Down Syndrome and rare systemic diseases like Hyperinsulinemia Hyperammonemia syndrome (HHS or HI/HA) and cardiac amyloidosis. Management argue that current treatments for AD aim to maintain functional capability do not address underlying cause of the disease and thus have been unsuccessful in delaying disease progression. HHS is a rare genetic disease triggering severe recurrent hypoglycemia and elevated levels of ammonia that results in liver, kidney, and CNS complications, brain damage and death. Diazoxide has been used to treat hypoglycemia in HHS but may not treat neurological symptoms as it does not address the underlying cause of HHS.
